Development of Small Molecule Enhancer Formulations for Optimized AAV Production in the ELEVECTA™ Transient Cell Line

his poster highlights Virica’s collaboration with Cytiva and eXmoor Pharma to optimize AAV production in the ELEVECTA™ transient cell line using Viral Sensitizer VSE™ technology. Through High Throughput Virology (HTV™) screening and formulation development, Virica identified VSE combinations that delivered 2 to 4-fold improvements in AAV titer across multiple serotypes and scales, including 10 L AAV8 validation. Further, BioSolve modeling showed that a 3x upstream yield improvement could reduce AAV manufacturing cost per dose by approximately 63 percent, supporting a scalable path to higher productivity and lower COGs.